Compare Heron Therapeutics Inc (HRTX) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Health Care Select Sector SPDR Fund — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Health Care Select Sector SPDR Fund trades at $159.69. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | XLV | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | — |
52-Week High | $1.96 | $164.48 |
52-Week Low | $0.39 | $129.01 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
XLV trades at $159.25, down 1.14% on the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The healthcare ETF faces mixed sentiment with recent positive sector upgrades from State Street Investment Management but concerns about sector headwinds during earnings season. Support levels cluster around $158-160, while resistance sits at $163-165.
The healthcare sector offers defensive characteristics amid market volatility, with XLV providing diversified exposure. Key risks include patent cliffs for major holdings and election-year policy uncertainty. Analyst sentiment is cautiously optimistic given the sector's stability and innovation pipeline, though relative performance versus technology remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
